-
ASCO 2026 | Prof. Li Mao: Ensartinib Differentiates Itself in the Global ALK Landscape and Accelerates Its International Expansion
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the treatment landscape for ALK-positive non-small cell lung cancer (NSCLC) continued to evolve, with major updates from landmark studies including CROWN, ALKOVE-1, and TRIDENT-1 reshaping global competition among ALK inhibitors.
-
2-Year PFS Rate Significantly Improved by 8.2%! FRONTMIND Study Confirms Tafa+Len+R-CHOP Improves Prognosis in Previously Untreated High-Risk DLBCL Patients
At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Georg Lenz from the University of Münster, Germany, on behalf of the FRONTMIND study group, delivered an oral presentation on the final analysis results of the Phase 3 FRONTMIND study. This study aimed to investigate the efficacy and safety of adding the CD19 monoclonal antibody…
-
From Genetic Drivers to Precision Prevention: Professor George Vassiliou Awarded the EHA Research Excellence Award, Leading a Shift in Myeloid Malignancy Prevention and Treatment
At the 2026 European Hematology Association (EHA) Annual Meeting, the association presented the “EHA Research Excellence Award” to Professor George Vassiliou from the University of Cambridge and the Wellcome Sanger Institute, in recognition of his pioneering contributions to the fields of biology, pathogenesis, and early intervention in myeloid malignancies. In the subsequent award lecture, Professor…
-
Challenges and Perseverance: Large Randomized Controlled Trial Confirms ATG Superiority Over PTCy in Unrelated Donor HCT, Significantly Reducing Non-Relapse Mortality
At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Johannes Schetelig from the Technical University Dresden and the German Bone Marrow Donor Center (DKMS) presented a highly anticipated Late-breaking Abstract. This study is a large-scale randomized controlled trial (RCT) designed to compare Anti-T Lymphocyte Globulin (ATLG) and Post-Transplant Cyclophosphamide (PTCy) “head-to-head” for the prophylaxis…
-
EHA 2026 Clinical Excellence Awardee Prof. Josep Maria Ribera: Crossing 40 Years to Open a New Era of Precision Treatment for Acute Lymphoblastic Leukemia
At the 2026 European Hematology Association (EHA) Annual Meeting, Prof. Josep Maria Ribera from the Josep Carreras Leukemia Research Institute and the Catalan Institute of Oncology (ICO) was honored with the “EHA Clinical Excellence Award.” In his subsequent award lecture, Prof. Ribera systematically reviewed the successful transformation of Acute Lymphoblastic Leukemia (ALL) from a “diagnostic…
-
Breaking the MM Treatment Burden: Precision Prevention of Infection, Optimization of Administration Routes, and Future Outlook for Trispecific Antibodies
At the 2026 European Hematology Association (EHA) Annual Meeting, managing the treatment burden of multiple myeloma (MM) became a core topic. As innovative therapies such as bispecific antibodies (BsAbs) and CAR-T enter clinical practice, how to reduce patient infection risks, optimize the convenience of administration, and improve quality of life while pursuing deep remission has…
-
EHA 2026 Highlight: Prof. Lars Bullinger Deciphers 25 Years of Molecular Hematology Evolution—From Gene Expression Profiles to Precision Diagnosis and Treatment Profiles
In the Presidential Session of the 2026 European Hematology Association (EHA) Annual Meeting, Prof. Lars Bullinger from Charité – Universitätsmedizin Berlin delivered a keynote speech titled “From gene profiles to therapy profiles – a quarter century of molecular hematology.” Combining his personal research experience with global major scientific breakthroughs, Prof. Bullinger provided a profound analysis…
-
Second-generation vs. First-generation FLT3 Inhibitors: PASHA Study Reveals Clinical Benefits and Challenges of Gilteritinib Combined with First-line Intensive Chemotherapy
In the treatment of acute myeloid leukemia (AML), the FLT3 mutation is one of the most common genetic abnormalities (accounting for approximately 30%), and the evolution of its treatment strategies has always been a focus of clinical attention. Although the first-generation FLT3 inhibitor midostaurin and the second-generation inhibitor quizartinib have been approved for first-line treatment,…
Connecting Medical Expertise through Media